Critical Pharmaceuticals today announces the results of a long-term preclinical study that confirms the excellent local tolerability of its unique and proprietary CriticalSorb nasal drug delivery technology. The biotechnology company is now preparing to take the technology forward into a phase I clinical trial.
CriticalSorb is already used in a number of marketed drugs for intravenous and oral administration and the results of this study complete the toxicology package for the nasal route of administration.
CriticalSorb is a best in class absorption promoter that enables the nasal delivery of biological and challenging small molecule drugs. Biological drugs represent a $90 billion market, and yet nearly all need to be administered by frequent injection. CriticalSorb has the potential to transform the delivery of biological drugs by enabling non-invasive delivery that would be strongly preferred by patients.
Showing posts with label Critical Pharmaceuticals. Show all posts
Showing posts with label Critical Pharmaceuticals. Show all posts
Tuesday, 8 March 2011
Subscribe to:
Posts (Atom)